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Abstract 
Background: Betatrophin has been recently reported to play a role in glucose homeostasis by inducing beta-cell 
proliferation in mice. However, studies in human are inconsistent. As a nutritionally-regulated liver-enriched factor, 
we hypothesize that betatrophin might be regulated by vitamin D, and ignorance of vitamin D status may explain 
the discrepancy in previous human studies. The aims of this study were to assess the association between circulat-
ing betatrophin and glucose homeostasis as well as other cardiometabolic variables in a cohort of youths at risk for 
metabolic syndrome and test the possible influence of vitamin D status on the association.
Methods: 559 subjects aged 14–28 years were recruited from Beijing children and adolescents metabolic syndrome 
study. All underwent a 2 h-oral glucose tolerance test. Serum levels of betatrophin, 25-hydroxy-vitamin D as well as 
adipokines including adiponectin and fibroblast growth factor 21 (FGF21) were measured by immunoassays. The rela-
tionships between betatrophin and insulin resistance, beta-cell function, other cardiometabolic variables and vitamin 
D status were evaluated.
Results: Participants in the highest quartile of betatrophin levels had the highest levels of total cholesterol 
(P < 0.001), triglyceride (P < 0.001) and low-density lipoprotein cholesterol (P < 0.001) and the lowest levels of vitamin 
D (P = 0.003). After stratification by vitamin D status, betatrophin in subjects with vitamin D deficiency were positively 
correlated with unfavorable metabolic profiles including high blood pressures, dyslipidemia and hyperglycemia, 
whereas betatrophin in those with higher vitamin D levels only showed negative association with fasting insulin, 
2 h-insulin, and insulin resistance. In addition, adiponectin and FGF21 demonstrated the expected associations with 
metabolic parameters.
Conclusions: Elevated betatrophin levels were associated with cardiometabolic risk factors in this young population, 
but the association was largely dependent on vitamin D status. These findings may provide valuable insights in the 
regulation of betatrophin and help explain the observed discrepancies in literature.
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Background
Betatrophin is a nutritionally-regulated secreted protein 
encoded by the Gm6484 gene in mice and C19orf80 in 
humans, and is expressed primarily in liver and adipose 
tissue [1]. Betatrophin was also named as RIFL (refeed-
ing-induced fat and liver), Lipasin and angiopoietin-like 
protein 8 (ANGPTL8), and was initially implicated in 
lipid metabolism [2]. Recently Yi and colleagues found 
betatrophin can promote pancreatic beta-cell prolif-
eration, improve glucose tolerance under insulin resist-
ance (IR) and thus was named as betatrophin [3]. These 
results suggest that betatrophin not only plays a role in 
promoting glucose metabolism but also represents a 
promising drug target for replenishing beta-cell mass. 
Although later experimental studies challenged the ini-
tial indications about the role of betatrophin in regula-
tion of beta-cell function [4–6], its role in regulating lipid 
metabolism has been confirmed by several other studies 
[7–9]. Despite the potential important metabolic role 
of betatrophin in mice, knowledge about betatrophin in 
humans is still inconsistent and controversial [10–24]. 
For instance, betatrophin levels were variable in type 2 
diabetes mellitus (T2DM), either increased [11–14, 23] 
or decreased [15, 22], and similar patterns were observed 
in obesity [13, 15, 17–20] and IR [10–12, 15, 21, 22].
Despite the consensus on the involvement of betatro-
phin in lipid metabolism, the precise mechanism in this 
process remains unclear. The proposed mechanism is 
that betatrophin inhibits lipoprotein lipase (LPL) [25], 
and therefore in Angptl8 knockout mice, the lower tri-
glyceride (TG) phenotype is likely due to increased LPL 
activity [26]. Interestingly, vitamin D as one of the essen-
tial nutrients plays an important role in lipid metabolism, 
which is likely mediated by LPL pathway because it can 
induce LPL expression and increase LPL activity in adi-
pocytes [27] and is positively associated with LPL  con-
centration [28]. Moreover, previous studies indicated 
that betatrophin expression was regulated by nutritional 
intake [1], we thus hypothesize that vitamin D might also 
be served as a nutrient to regulate the expression and 
function of betatrophin. To date, no study has examined 
the role of vitamin D in mediating or modifying the asso-
ciation between betatrophin and metabolism. Thus, in 
the present study, we assessed the associations between 
circulating betatrophin levels and cardiometabolic risk 
factors including obesity, high blood pressure, dyslipi-
demia, IR, hyperglycemia and test whether these associa-
tions are affected by vitamin D conditions in a cohort of 
Chinese youth at risk for metabolic syndrome (MS).
Recent studies demonstrated that some adipokines, 
such as adiponectin, and fibroblast growth factor 21 
(FGF21), were beneficial for improving metabolic effects 
[29]. However, few data are available regarding the rela-
tionship between betatrophin and these adipokines. 
Therefore, we also analyzed two well-known adipokines-
adiponectin and FGF21 in similar models to assess their 
associations with cardiometabolic risk factors and to pro-
vide validity for our study.
Methods
Participants
A total of 559 subjects (14–28 years, mean = 20.2 years) 
were recruited from the cohort of Beijing children and 
adolescents metabolic syndrome (BCAMS) study. The 
BCAMS cohort study evaluated the prevalence of obe-
sity and related metabolic abnormalities (hypertension, 
hyperglycemia, dyslipidemia) among a representative 
sample of Beijing school-age children (n =  19,593, ages 
6–18 years, 50 % male) between April and October 2004 
[30]. In this cohort, 4500 subjects were identified as hav-
ing one or more of the following disorders: overweight 
defined by body mass index (BMI), increased total cho-
lesterol (TC) ≥5.2 (mmol/L), TG ≥1.7 (mmol/L) or 
fasting glucose (FBG) ≥5.6 (mmol/L) based on finger 
capillary blood tests. We conducted follow up study after 
10  years of initial investigation. Subjects were recruited 
consecutively over an 18-month period through vari-
ous modalities and underwent medical examination in 
a center at Beijing Chaoyang Hospital. Signed informed 
consent was obtained from all participants and/or their 
parents or guardians through all the study processes. The 
BCAMS study was approved by the ethics committee at 
Beijing Chaoyang Hospital.
Clinical and biochemical measurements
Subjects’ height, waist circumference (WC), weight, per-
cent body fat, systolic and diastolic blood pressure (SBP 
and DBP) were measured by trained recruiters using 
standard methods. Participants removed bulky clothing 
and shoes prior to measurements. Height was measured 
to the nearest 0.1 cm using a portable stadiometer. WC 
was measured midway between the lowest rib and the top 
of the iliac crest. Weight and percent body fat were meas-
ured to the nearest 0.1  kg using a TANITA body com-
position analyzer (ModelTBF–300A). Measurements of 
right arm SBP and DBP were performed 3 times 10 min 
apart and the mean value of the latter two measurements 
was recorded. BMI was calculated as weight divided by 
height squared.
Venous blood samples were collected after an over-
night (≥12 h) fasting. The samples were centrifuged, and 
immediately frozen for future analysis of hormones. A 
2  h–75  g oral glucose tolerance test (OGTT) was per-
formed on each subject. Serum lipids and glucose were 
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assayed using the Hitachi 7060 C automatic biochemis-
try analysis system. Low density lipoprotein cholesterol 
(LDL-C) and high density lipoprotein cholesterol (HDL-
C) levels were measured directly. HbA1c was assayed 
using the TOSOH G7 automatic analysis system. Serum 
aspartate transaminase (AST), alanine aminotransferase 
(ALT), creatinine and uric acid levels were assayed using 
automatic biochemistry analysis system and serum 
25-hydroxy-vitamin D levels were measured by elec-
tro-chemiluminescence immunoassay with intra-assay 
and inter-assay coefficient of variations (CVs) of <7.5 
and <6.8  %. Serum betatrophin levels were measured 
using enzyme-linked immunosorbent assay (ELISA) kits 
(WUHAN Eiaab Science; catalog number E11644 h) with 
intra- and inter- assay CVs of <8 and <10 %, respectively. 
The procedures were performed in accordance with the 
manufacturer’s instructions and the detection range was 
78.0–5000  pg/ml, respectively. Insulin and adiponec-
tin was measured by monoclonal antibody based ELISA 
[30] developed in the Key Laboratory of Endocrinology, 
Peking Union Medical College Hospital. Insulin assay 
had an inter-assay CV of <9.0 % and no cross-reactivity 
to proinsulin (<0.05  %). The intra-assay and inter-assay 
CVs for adiponectin were <5.4 and <8.5  %, respectively 
[31]. FGF21 was measured by Human Quantikine ELISA 
Kit (R&D Systems, Inc.) with intra- and inter-assay CVs 
of <4.8 and <7.4  %, respectively. All samples were ana-
lyzed in duplicates.
Definitions and diagnostic criteria
IR was estimated using the following index: (1) homeo-
stasis model assessment of IR (HOMA-IR) as fasting 
insulin(FINS) mU/L  ×  FBG mmol/L/22.5; (2) insulin 
sensitive index (Matsuda Index) (ISIM), ISIM  =  10,000/
(FBG × FINS) × (G × I), where G = mean serum glucose, 
and I = mean serum insulin concentration [32]. Pancre-
atic beta-cell function was assessed by (1) insulinogenic 
index (IGI = △Ins30/△Gluc30) and (2) oral disposition 
index (DIO = IGI × ISI) which was the product of insulin 
sensitivity and insulin secretion, yielded a better meas-
ure of beta-cell function [33]. The diagnosis of impaired 
fasting glucose (IFG), impaired glucose tolerance (IGT), 
prediabetes and T2DM profiles were based on the diag-
nostic criteria of American Diabetes Association [34]. 
IFG: FBG levels from 5.6 to 6.9 mmol/L; IGT: 2-h blood 
glucose (2 h-BG) levels from 7.8 to 11.0 mmol/L; predia-
betes, IFG or IGT; T2DM: FBG ≥7.0 mmol/L or 2 h-BG 
≥11.1 mmol/L. Nonalcoholic fatty liver disease (NAFLD) 
was diagnosed by B ultrasonography according to the 
2010 Prevention and Treatment Guidelines for NAFLD 
published by the Society of Hepatology, Chinese Medi-
cal Association [35]. Vitamin D is deficient if ≤15 ng/mL 
[36].
MS in adolescents was defined by the presence of 
three or more of the following five components [30]: 
(1) central obesity: WC ≥90th percentile for age and 
gender in 10–16  years, WC ≥90  cm for boys and WC 
≥80 cm for girls in over 16 years old; (2) elevated SBP/
DBP ≥90th percentile for age, gender in 10–16  years, 
SBP ≥130 mm Hg or DBP ≥85 mm Hg for subjects over 
16 years; (3) HDL-C <1.03 mmol/l in males, <1.29 mmol/l 
in females; (4) TG ≥1.70  mmol/l; (5) IFG defined as 
≥5.6 mmol/L.
Statistical analysis
Analyses were performed using Statistical Package for 
Social Sciences (SPSS) 19.0. A P value <0.05 (two-sided) 
was considered statistically significant. All skewed dis-
tributions were natural logarithmically transformed for 
analysis. Student’s t test and one-way ANOVA with Bon-
ferroni’s post hoc comparisons were used for continuous 
variables. Partial correlation coefficients were calculated 
to evaluate the association between betatrophin and 
anthropometric measurements as well as other biomark-
ers associated with cardiovascular diseases.
Results
Demographic and clinical characteristics of study sub-
jects were listed in Table 1. The study includes 559 unre-
lated individuals recruited through the BCAMS study, 
53  % of the participants were male, and the mean age 
was 20.2 ± 2.9 years. Compared to female subjects, male 
participants had higher BMI (P < 0.001), WC (P < 0.001), 
SBP (P < 0.001), DBP (P < 0.001), TG (P = 0.001), FBG 
(P = 0.001), 0.5 h-BG (P < 0.001) and HbA1c (P = 0.035) 
levels and lower HDL-C (P < 0.001) and DIO (P < 0.001) 
levels. As expected, females had higher adiponectin con-
centrations (P  <  0.001) than males. However, there was 
no significant gender difference in FGF21. For betatro-
phin, the level in females was lower than that in males 
(P < 0.001).
To evaluate the relationships between betatrophin and 
cardiometabolic risk factors, participants were further 
divided into quartiles based on sex-standardized betatro-
phin levels. As shown in Table 2, subjects in the highest 
betatrophin quartile exhibited the highest levels of TC 
(P < 0.001), TG (P < 0.001) and LDL-C (P < 0.001) and the 
lowest levels of vitamin D (P = 0.003). However, no dif-
ference was observed for obesity traits, blood pressures, 
HDL-C, blood glucose/insulin traits, and adipokines with 
betatrophin levels.
Next, we compared betatrophin levels across various 
metabolic abnormalities (Fig.  1). After controlling for 
age and gender, serum betatrophin concentrations were 
significantly increased in subjects with high TG levels 
(P  =  0.001) and with lowest tertile of vitamin D levels 
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(P = 0.013), and tended to be higher in T2DM (P = 0.059 
vs. normal subjects; P  =  0.137 vs. IFG/IGT). However, 
circulating betatrophin levels were not significantly dif-
ferent between those with and without central obesity, 
elevated blood pressures and NAFLD (all P  >  0.05). In 
addition, betatrophin levels were not significantly dif-
ferent among the groups with different numbers of MS 
components (P > 0.05).
In order to investigate whether the correlations 
between betatrophin and metabolic parameters were 
affected by vitamin D status, we further stratified par-
ticipants into two groups according to vitamin D levels, 
as shown in Table  3. In the whole-population, betatro-
phin levels were negatively correlated with vitamin D 
(P < 0.001), and positively correlated with TC (P < 0.001), 
TG (P = 0.024), LDL-C (P = 0.002), HbA1c (P = 0.005), 
as well as creatinine (P < 0.001), uric acid (P = 0.001) and 
adiponectin (P  =  0.044). No association was observed 
between betatrophin and measures of adiposity. In 
the vitamin D deficient group (vitamin D  ≤  15  ng/ml), 
we observed more significant correlations with above 
mentioned variables. Additionally, betatrophin levels 
were positively correlated with SBP (P  =  0.004), DBP 
(P = 0.001), 2 h-BG (P = 0.016) and negatively correlated 
with DIO (P = 0.025). However, these associations were 
not observed in the vitamin D > 15 ng/ml group except 
for creatinine (P  =  0.024). Nonetheless, in the vitamin 
D  >  15  ng/ml group, betatrophin was positively corre-
lated with ISIM (P =  0.019) and negatively related with 
FINS (P  =  0.023), 2  h-INS (P  =  0.019), and HOMA-
IR (P  =  0.038). Figure  2 summarizes the associations 
between betatrophin and cardiometabolic variables and 
the possible influence of vitamin D levels.
Further, we examined the relationships between adi-
ponectin and FGF21 using similar models (Additional 
file 1: Table S1). As expected, FGF21 levels were positively 
correlated with obesity traits (P < 0.001), blood pressures 
(P < 0.001), lipid profiles and unfavorable blood glucose/
insulin traits (all P < 0.05), whereas adiponectin had the 
opposite  correlations with metabolic profiles compared 
with FGF21, but these associations were not modified by 
the way of vitamin D influencing on betatrophin.
Discussion
In this young population with risk for MS, we demon-
strated that increased betatrophin levels were associated 
with higher lipids (i.e. TG, TC and LDL-C) even after 
controlling for BMI, but no significant difference was 
observed in subjects with and without central obesity, 
high blood pressure, MS and NAFLD. Our novel find-
ing is that circulating betatrophin was increased in sub-
jects with vitamin D deficiency and the associations with 
Table 1 General characteristics of  study subjects accord-
ing to gender
Values in italics are significant at P < 0.05
BMI body mass index; WC waist circumference; SBP Systolic blood pressure; 
DBP Diastolic blood pressure; TC total cholesterol; TG triglycerides; LDL-C low 
density lipoprotein cholesterol; HDL-C high-density lipoprotein cholesterol; 
HOMA-IR homeostasis model assessment for insulin resistance; ISIM insulin 
sensitivity Matsuda index; IGI insulinogenesis index; DIO oral disposition index; 
AST aspartate aminotransferase; ALT alanine aminotransferase; FGF21 fibroblast 
growth factor 21
a Skewed distributions were natural logarithmically transformed. Vitamin D was 
adjusting for visiting season. Data were expressed as n (%), mean ± SD. P values 
are from Student’s t test
Parameters All Male Female P Value
N (%) 559 294 (53 %) 265 (47 %) /
Age (years) 20.2 ± 2.9 20.0 ± 3.0 20.4 ± 2.8 0.110
Obesity traits
BMI (kg/m2) 25.7 ± 5.7 27.0 ± 5.8 24.3 ± 5.3 <0.001
WC (cm) 85.2 ± 14.6 90.5 ± 14.6 79.4 ± 12.1 <0.001
Percent body fat 30.4 ± 10.3 27.9 ± 9.4 33.2 ± 10.5 <0.001
Pressures (mmHg)
SBP 114.7 ± 14.0 120.5 ± 13.8 108.2 ± 11.2 <0.001
DBP 73.2 ± 10.5 75.9 ± 10.3 70.2 ± 9.8 <0.001
Lipids (mmol/l)
TC 4.35 ± 0.92 4.29 ± 0.86 4.41 ± 0.99 0.131
TG 1.13 ± 0.83 1.25 ± 1.01 1.01 ± 0.54 0.001
LDL-C 2.53 ± 0.79 2.56 ± 0.72 2.50 ± 0.86 0.371
HDL-C 1.44 ± 0.32 1.34 ± 0.28 1.54 ± 0.34 <0.001
Glucose and insulin-related traits
Glucose0 (mmol/l) 4.92 ± 0.69 5.01 ± 0.86 4.82 ± 0.41 0.001
Glucose30 (mmol/l) 7.94 ± 1.51 8.17 ± 1.60 7.69 ± 1.36 <0.001
Glucose120 
(mmol/l)
6.06 ± 1.84 6.17 ± 2.07 5.95 ± 1.54 0.179
HbA1c (%) 5.38 ± 0.48 5.42 ± 0.54 5.33 ± 0.40 0.035
Insulin0 (mU/L)
a 1.94 ± 0.74 1.97 ± 0.75 1.89 ± 0.72 0.219
Insulin30 (mU/L)
a 4.26 ± 0.72 4.27 ± 0.74 4.24 ± 0.71 0.636
Insulin120 (mU/L)
a 3.61 ± 0.80 3.55 ± 0.86 3.67 ± 0.73 0.106
HOMA-IRa 0.41 ± 0.77 0.46 ± 0.77 0.35 ± 0.75 0.092
ISIM
a 1.79 ± 0.65 1.76 ± 0.66 1.82 ± 0.64 0.278
IGIa 0.22 ± 0.81 0.16 ± 0.79 0.27 ± 0.82 0.127
DIOa 2.01 ± 0.77 1.93 ± 0.73 2.09 ± 0.81 0.015
Hepar and renal-related traits
AST (IU/L)a 2.94 ± 0.32 3.02 ± 0.36 2.86 ± 0.25 <0.001
ALT (IU/L)a 2.96 ± 0.54 3.16 ± 0.55 2.75 ± 0.43 <0.001
Creatinine 
(umol/L)a
4.19 ± 0.23 4.32 ± 0.14 4.04 ± 0.21 <0.001
Uric acid (umol/L)a 5.84 ± 0.27 6.00 ± 0.21 5.66 ± 0.21 <0.001
Adipokines
FGF21 (pg/ml)a 4.39 ± 1.12 4.39 ± 1.11 4.39 ± 1.13 0.986
Adiponectin (μg/
mL)a
1.90 ± 0.65 1.75 ± 0.72 2.07 ± 0.53 <0.001
Betatrophin (pg/
ml)a
5.77 ± 0.37 5.82 ± 0.36 5.71 ± 0.37 <0.001
Vitamin D (ng/ml)a 2.64 ± 0.41 2.76 ± 0.40 2.52 ± 0.38 <0.001
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Table 2 Relationship between sex-standardized betatrophin quartiles and cardiometabolic risk factors
Data were expressed as n (%), mean ± SD
One-way ANOVA where differences versus quintile 1 are indicated as * P < 0.05, differences versus quintile 2 are indicated as + P < 0.05, differences versus quintile 3 
are indicated as $ P < 0.05. Quartile values of betatrophin are expressed as Q1, Q2, Q3 and Q4 (pg/ml). For female: Q1, 127.5–41.8; Q2, 241.8–87.0; Q3, 287.0–56.9; Q4, 
356.9–438.5. For male: Q1, 142.2–76.8; Q2, 276.8–29.3; Q3, 329.3–89.5; Q4, 389.5–475.6
Values in italics are significant at P < 0.05
BMI body mass index; WC waist circumference; SBP Systolic blood pressure; DBP Diastolic blood pressure; TC total cholesterol; TG triglycerides; LDL-C low density 
lipoprotein cholesterol; HDL-C high-density lipoprotein cholesterol; HOMA-IR homeostasis model assessment for insulin resistance; ISIM insulin sensitivity Matsuda 
index; IGI insulinogenesis index; DIO oral disposition index; AST aspartate aminotransferase; ALT alanine aminotransferase; FGF21 fibroblast growth factor 21
a Skewed distributions were natural logarithmically transformed. Vitamin D was adjusting for visiting season
Parameters Betatrophin P value
Q1 (n = 138) Q2 (n = 139) Q3 (n = 138) Q4 (n = 138)
Male gender, n (%) 73 (52.9 %) 73 (52.5 %) 73 (52.9 %) 73 (52.9 %) /
Age (years) 20.5 ± 3.1 20.0 ± 2.8 19.8 ± 2.9 20.4 ± 2.9 0.170
Obesity traits
BMI (kg/m2) 25.5 ± 5.5 24.7 ± 5.2 25.9 ± 6.0 26.6 ± 5.9 0.051
WC (cm) 85.1 ± 13.8 83.1 ± 13.5 85.2 ± 15.5 87.3 ± 15.2 0.120
Percent body fat 30.1 ± 10.2 29.4 ± 9.5 30.2 ± 10.3 31.5 ± 10.4 0.346
Pressures (mm Hg)
SBP 115 ± 14.9 113 ± 12.1 115 ± 13.5 116 ± 15.5 0.331
DBP 72 ± 10.7 73 ± 10.5 72.9 ± 9.5 75 ± 11.3 0.402
Lipids (mmol/l)
TC 4.27 ± 0.82 4.19 ± 0.82 4.29 ± 0.79 4.65 ± 1.17*,+,$ <0.001
TG 0.98 ± 0.53 1.02 ± 0.44 1.17 ± 0.85* 1.37 ± 1.23*,+ <0.001
LDL-C 2.49 ± 0.71 2.40 ± 0.73 2.47 ± 0.66 2.77 ± 0.98*,+,$ <0.001
HDL-C 1.44 ± 0.29 1.42 ± 0.31 1.43 ± 0.35 1.45 ± 0.34 0.870
Glucose and insulin-related traits
Glucose0 (mmol/l) 4.86 ± 0.51 4.97 ± 1.12 4.89 ± 0.44 4.95 ± 0.48 0.495
Glucose30 (mmol/l) 7.79 ± 1.33 7.99 ± 1.80 7.91 ± 1.42 8.05 ± 1.43 0.545
Glucose120 (mmol/l) 5.92 ± 1.30 6.01 ± 2.68 6.18 ± 1.45 6.15 ± 1.65 0.631
HbA1c (%) 5.34 ± 0.37 5.42 ± 0.66 5.35 ± 0.36 5.40 ± 0.48 0.515
Insulin0 (mU/L)
a 1.91 ± 0.71 1.88 ± 0.66 1.96 ± 0.74 1.98 ± 0.84 0.665
Insulin30 (mU/L)
a 4.30 ± 0.72 4.20 ± 0.63 4.31 ± 0.76 4.20 ± 0.78 0.460
Insulin120 (mU/L)
a 3.61 ± 0.79 3.53 ± 0.79 3.61 ± 0.70 3.65 ± 0.90 0.661
HOMA-IRa 0.37 ± 0.75 0.36 ± 0.70 0.43 ± 0.75 0.46 ± 0.87 0.636
ISIM
a 1.79 ± 0.65 1.83 ± 0.58 1.77 ± 0.65 1.79 ± 0.72 0.872
IGIa 0.29 ± 0.84 0.16 ± 0.76 0.26 ± 0.83 0.16 ± 0.80 0.423
DIOa 2.09 ± 0.87 2.00 ± 0.79 2.02 ± 0.65 1.93 ± 0.77 0.436
Hepar and renal-related traits
AST (IU/L)a 2.91 ± 0.25 2.96 ± 0.35 2.94 ± 0.28 2.97 ± 0.39 0.412
ALT (IU/L)a 2.92 ± 0.49 2.94 ± 0.52 2.95 ± 0.53 3.04 ± 0.60 0.248
Creatinine (umol/L)a 4.17 ± 0.19 4.19 ± 0.23 4.19 ± 0.19 4.22 ± 0.28 0.333
Uric acid (umol/L)a 5.80 ± 0.26 5.83 ± 0.25 5.86 ± 0.30 5.88 ± 0.27 0.098
Adipokines
FGF21 (pg/ml)a 4.41 ± 1.00 4.34 ± 1.03 4.44 ± 1.16 4.41 ± 1.30 0.914
Adiponectin (μg/mL)a 1.88 ± 0.65 1.94 ± 0.57 1.90 ± 0.68 1.89 ± 0.75 0.885
Betatrophin (pg/ml)a 5.37 ± 0.15 5.66 ± 0.09* 5.82 ± 0.08*,+ 6.24 ± 0.43*,+,$ <0.001
Vitamin D (ng/ml)a 2.70 ± 0.36 2.70 ± 0.41 2.64 ± 0.35 2.53 ± 0.47*,+ 0.003
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blood pressures, lipids, glucose/insulin traits, creatinine 
and uric acid were largely dependent on vitamin D status. 
In addition, this study replicated the well-known nega-
tive association of adiponectin and positive association of 
FGF21 with MS-related risk factors [29].
The associations of betatrophin and cardiometabolic 
variables without consideration of vitamin D status
Betatrophin was initially implicated in lipid metabo-
lism, as expected, our study confirmed the previous 
findings that circulating betatrophin was positively cor-
related with TG, TC and LDL-C, but not with HDL-C 
[7–9]. Besides its role in lipid regulation, betatrophin 
is also expected to play as a novel hormone to regulate 
glucose homeostasis in human as its function in mice 
[3]. However, results from adult clinical studies were 
controversial, for example, some studies reported that 
circulating betatrophin levels were positively correlated 
with HbA1c [11, 14] and increased in T2DM [11–14], 
while others exhibited decreased betatrophin concentra-
tions in T2DM as well as obesity [15, 22]. Furthermore, 
two recent studies focus on children and adolescents also 
reported controversial results, betatrophin levels either 
decreased [20] or increased in obesity children with IR 
[10]. In our study, we found betatrophin was positively 
correlated with HbA1c, but only slightly elevated in 
T2DM patients compared to normoglycemic and predia-
betic subjects, although the numbers of the young T2DM 
(9 cases) were too small to make a safe conclusion. How-
ever, no significant difference existed between individu-
als with and without obesity or MS. These discrepancies 
might be due to different study populations, or the use of 
different ELISA kits that recognize different terminus of 
betatrophin [37]. However, here we showed that another 
explanation is the confounding due to vitamin D status.
The associations of betatrophin and cardiometabolic 
variables by vitamin D status
The effects of vitamin D on glucose and lipid metabo-
lism have been investigated extensively in recent years 
[38]. Low vitamin D levels, have been found to contrib-
ute to various CVD risk factors, such as hypertension, 
atherosclerosis, coronary artery disease and stroke [39]. 
In this study, we found vitamin D levels were negatively 
associated with circulating betatrophin concentra-
tion, and subjects in the lowest tertile of vitamin D lev-
els had the highest betatrophin levels. Previous studies 
have indicated that vitamin D plays an important role 
in the lipid metabolism by inducing LPL expression and 
increasing LPL activity in adipocytes [27], and the posi-
tive correlation between vitamin D and LPL levels were 
also confirmed in a population  study [28]. Interestingly, 
betatrophin is also referred to as Lipasin for its LPL inhi-
bition effect. Given these observations, we speculated 
that vitamin D might be a major regulator of betatrophin 
expression, and they may also interact with each other, 
involved not only in lipid metabolism through the path-
way of LPL, but also in other cardiometabolic regulation. 
Therefore, we further analyzed the associations between 
betatrophin and lipid/glucose parameters, and other car-
diometabolic risk factors through stratifying the partici-
pants into two groups according to vitamin D levels. As 
we expected, the associations between betatrophin and 
cardiometabolic parameters depend largely on vitamin D 
status (as summarized in Fig. 2).
Firstly, we found the correlations between betatrophin 
and lipid profiles are more significant in the vitamin D defi-
ciency group and disappeared in the higher levels of vitamin 
D group. The possible mechanisms between betatrophin 
and lipid profiles are as follows: Firstly, both betatrophin and 
vitamin D play important roles in lipid metabolism. Beta-
trophin inhibits LPL activity to elevate TG levels, whereas 
vitamin D stimulates LPL activity to decrease TG levels, 
they coordinate with each other to keep a balance of lipid 
metabolism. Subjects with vitamin D deficiency display a 
reduction of LPL activity and a compensatory secretion 
of betatrophin and then lead to the increasing of serum 
lipids levels and this effect disappeared when vitamin D 
is not deficient. Secondly, while it is not possible to deter-
mine causality with the present design, available data have 
shown that vitamin D is hydroxylated in the 25 position to 
yield 25-hydroxyvitamin D in liver, meanwhile, betatrophin 
mainly expressed in liver; we thus speculate that there might 
exist a direct reciprocal down-regulation between those two 
hormones in liver; however, further experimental study with 
focus on their direct interaction in liver may help explain 
the findings in current study. In addition, it should be noted 
that a few other studies found no correlation between 
(See figure on previous page.) 
Fig. 1 Levels of betatrophin in various metabolic abnormalities. Betatrophin concentrations were compared between subjects with and without a 
central obesity, b elevated blood pressures, c high TG, d low HDL-C and g NAFLD, and subjects with different e glucose tolerance status (nor-
mal, IGT/IFG, or T2DM, f number of MS components (0, 1, 2, or ≥ 3) and h vitamin D tertile ( T1, 3.00–11.94 ng/ml; T2, 11.94–17.04 ng/ml; and T3, 
17.04–35.61 ng/ml). Data are natural log-transformed and shown as mean ± SEM. All P values were adjusted for gender and age and P* was further 
adjusted for vitamin D levels. NS no significant difference; TG triglycerides; HDL-C high-density lipoprotein cholesterol; MS metabolic syndrome; IFG 
impaired fasting glucose; IGT impaired glucose tolerance; T2DM type 2 diabetes mellitus; NAFLD nonalcoholic fatty liver disease
Page 8 of 12Fu et al. Cardiovasc Diabetol  (2016) 15:142 
betatrophin and lipid profiles [10, 11, 21]. In view of these 
inconsistent results, the underlying mechanism needs to be 
further studied in future studies beyond the possible path-
way mentioned above.
For glycometabolism, in the vitamin D deficiency 
group, betatrophin was positively correlated with HbA1c 
and 2  h-BG levels, and negatively correlated with DIO 
levels, whereas in subjects with higher levels of vitamin 
Table 3 Age- and gender- adjusted partial correlations coefficients between Ln-betrathrophin and metabolic parameters 
stratified by vitamin D status
Values in italics are significant at P < 0.05
BMI body mass index; WC waist circumference; SBP Systolic blood pressure; DBP Diastolic blood pressure; TC total cholesterol; TG triglycerides; LDL-C low density 
lipoprotein cholesterol; HDL-C high-density lipoprotein cholesterol; HOMA-IR homeostasis model assessment for insulin resistance; ISIM insulin sensitivity Matsuda 
index; IGI insulinogenesis index; DIO oral disposition index; AST Aspartate transaminase; ALT Alanine aminotransferase; FGF21 fibroblast growth factor 21




Variables All (n = 559) Vitamin D > 15 ng/ml (n = 250) Vitamin D ≤ 15 ng/ml 
(n = 309)
r P r P r P
Obesity traits
BMI (kg/m2) 0.033 0.435 0.024 0.708 0.044 0.442
WC (cm) 0.014 0.736 −0.034 0.593 0.064 0.270
Percent body fat −0.004 0.917 −0.012 0.856 0.002 0.978
Pressures (mmHg)
SBP 0.026 0.537 −0.119 0.063 0.163** 0.004
DBP 0.075 0.079 −0.041 0.519 0.186** 0.001
Lipids (mmol/l)
TC 0.155*** <0.001 0.048 0.456 0.271*** <0.001
TGa 0.096* 0.024 −0.001 0.993 0.170** 0.003
LDL-C 0.134** 0.002 0.018 0.780 0.247*** <0.001
HDL-C 0.022 0.611 0.076 0.236 −0.013 0.818
Glucose and insulin-related traits
Glucose0 (mmol/l) 0.041 0.331 0.048 0.456 0.036 0.531
Glucose30 (mmol/l) 0.070 0.109 0.018 0.786 0.107 0.067
Glucose120 (mmol/l) 0.074 0.090 −0.044 0.504 0.140* 0.016
HbA1c (%) 0.119** 0.005 0.074 0.246 0.161** 0.005
Insulin0 (mU/L)
a −0.025 0.551 −0.145* 0.023 0.079 0.173
Insulin30 (mU/L)
a −0.043 0.321 −0.097 0.138 0.003 0.953
Insulin120 (mU/L)
a −0.058 0.183 −0.153* 0.019 0.040 0.498
HOMA-IRa −0.016 0.709 −0.133* 0.038 0.084 0.144
ISIM
a 0.040 0.360 0.154* 0.019 −0.063 0.287
IGIa −0.083 0.060 −0.092 0.165 −0.077 0.192
DIOa −0.059 0.183 0.019 0.773 −0.133* 0.025
Hepatic and renal-related traits
AST (IU/L)a 0.040 0.345 0.068 0.289 0.020 0.723
ALT (IU/L)a 0.043 0.317 0.009 0.894 0.087 0.131
Creatinine (mg/dL)a 0.228*** <0.001 0.144* 0.024 0.319*** <0.001
Uric acid (mg/dL)a 0.136** 0.001 0.118 0.065 0.165** 0.004
Adipokines
FGF21 (pg/ml)a 0.004 0.933 −0.063 0.336 0.058 0.324
Adiponectin (μg/mL)a 0.086* 0.044 0.039 0.545 0.142* 0.013
Vitamin D (ng/ml)a −0.196*** <0.001 −0.069 0.306 −0.265*** <0.001
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D, betatrophin levels were negatively associated with 
insulin and HOMA-IR levels, and positively correlated 
with ISIM levels. As mentioned above, the expression 
of betatrophin may be up-regulated under the vitamin 
D deficiency status whereas suppressed under the high 
levels of vitamin D levels. Thus, at least in the present 
study, we did not observe the promising role of betatro-
phin in promoting insulin secretion or improving glucose 
tolerance as reported in mice [3]; conversely, we found 
increased betatrophin levels were associated increased 
HbA1c and glucose under vitamin D deficiency status; 
while a negative association between betatrophin lev-
els and HOMA-IR or insulin levels were only observed 
under higher vitamin D levels, which in line with a recent 
study including 75 children [20]. Since vitamin D defi-
ciency was very common in patients with IR or T2DM, 
thus, we speculated that vitamin D deficiency might 
responsible for the elevated betatrophin in T2DM or IR 
in previous reports [11–14].
Additionally, we found serum betatrophin concen-
trations were positively correlated with blood pres-
sures in vitamin D deficiency group. The positive 
associations between betatrophin and blood pres-
sures were reported in patients with GDM [40] or 
T2DM [41]. In addition, previous meta-analysis dem-
onstrated a significant inverse association between 
circulating 25(OH)D levels and risk of incident GDM 
[42] and T2DM [43]; and lower 25-hydroxyvitamin D 
levels were associated with higher blood pressure lev-
els and increased rates of incident hypertension [44]. 
Thus, the positive correlation between betatrophin 
and blood pressures in GDM or T2DM might also be 
attributed to vitamin D deficiency. However, since no 
other study is available, further studies are warranted 
to validate our findings.
In the present study, creatinine and uric acid are 
strongly positively correlated with betatrophin levels and 
the correlations are more significant in vitamin deficient 
Fig. 2 Possible associations between betatrophin and cardiometabolic variables and the influence of vitamin D status. SBP Systolic blood pressure; 
DBP Diastolic blood pressure; LPL lipoprotein lipase; TC total cholesterol; TG triglycerides; LDL-C low density lipoprotein cholesterol; HDL-C high-
density lipoprotein cholesterol; 2h-BG 2-hour blood glucose; FINS fasting insulin; 2h-INS 2-hour insulin; HOMA-IR homeostasis model assessment 
for insulin resistance; ISIM insulin sensitivity Matsuda index; DIO oral disposition index; AST Aspartate transaminase; ALT Alanine aminotransferase; 
NAFLD nonalcoholic fatty liver disease; FGF21 fibroblast growth factor 21. Color in red indicates the associations with increased concentrations of 
betatrophin possibly induced by vitamin D deficiency; color in dark blue indicates the associations with low concentrations of betatrophin possibly 
inhibited by higher levels of vitamin D; dotted black line represents the possible role of vitamin D in regulating betatrophin levels; N dash means no 
significant association
Page 10 of 12Fu et al. Cardiovasc Diabetol  (2016) 15:142 
group. In contrast, a cross-sectional study of 148 pregnant 
patients [45] found no correlation between circulating 
betatrophin levels and the markers of renal function. The 
potential mechanisms supporting the associations should 
be elucidated by further studies. Meanwhile, betatrophin 
is mainly expressed in liver and strongly associated with 
TG, therefore, circulating betatrophin levels are supposed 
to correlate with NAFLD [18]. However, we found no 
association between betatrophin and NAFLD, as well as 
the aminotransferase levels which have also been demon-
strated to be a marker of the severity of NAFLD.
The associations of betatrophin and adipokines
Our data suggest that circulating betatrophin levels are 
not correlated with FGF21 levels, but positively associ-
ated with adiponectin concentrations. Like betatrophin, 
FGF21 produced preferentially from liver, and function in 
multiple tissues, with beneficial metabolic effects such as 
reduction of body weight and liver fat, improvement of 
insulin sensitivity, antihyperglycemic, antihyperlipidemic 
and thermogenic properties [46]. The two hepatokines 
(betatrophin and FGF21) are not correlated with each 
other, suggesting their potential production and function 
mechanisms may be different. Adiponectin is the most 
abundant peptide secreted by adipocytes and is consid-
ered a potent modulator of lipid and glucose metabolism 
with antidiabetic, antiatherogenic and anti-inflammatory 
properties, and plays an important role in the pathogen-
esis of metabolic diseases [46]. Since there are no pub-
lished studies on the relationship between betatrophin 
and adiponectin, further studies should be conducted to 
investigate the mechanism of our findings.
Our study is the first that accounts for vitamin D con-
dition when assessing the relationships between beta-
trophin and cardiometabolic risk factors. Additionally, 
the replication of expected associations between impor-
tant adipokines (adiponectin and FGF21) and metabolic 
measurements provides validity and power in accordance 
with the methodology used here.
We recognize that this study has several limitations. 
The cross-sectional nature of this study does not allow 
the examination of temporal association or causality. 
Although the different biological relationships observed 
between betatrophin and variables of metabolism in dif-
ferent vitamin D nutritional status are likely universal, 
our sample was limited to a particular group of Chinese 
youths, thus, our findings may not be simply general-
ized to other populations. Further large sample stud-
ies in different ethnicities will be necessary to verify the 
relationships between betatrophin, vitamin D condition 
and cardiometabolic risk factors and find the direct evi-
dences to elucidate the regulatory pathway. In addition, 
the wide age range of our study population and the lack 
of puberty information in those of 14–18 years old ado-
lescents should also be recognized as the limitation, thus, 
to minimize this limitation, we adjusted for age, and sex 
when performing analysis.
In summary, our study demonstrated that betatrophin 
levels were increased with vitamin D deficiency. Fur-
thermore, the associations between betatrophin and car-
diometabolic risk factors including high blood pressures, 
dyslipidemia, and hyperglycemia were largely influenced 
by vitamin D status and were found exclusively among 
subjects with vitamin D deficiency. We believe that the 
lack of explanation for inconsistent results in the literature 
is due to the ignorance of vitamin D status, and further 
mechanistic studies are required to confirm this finding.
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